Dc. Suh et al., Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry, HEAL SERV R, 35(2), 2000, pp. 529-547
Citations number
28
Categorie Soggetti
Public Health & Health Care Science","Health Care Sciences & Services
Objective. To analyze the effect of multiple-source drug entry on price com
petition after patent expiration in the pharmaceutical industry.
Data Sources. Originators and their multiple-source drugs selected from the
35 chemical entities whose patents expired from 1984 through 1987. Data we
re obtained from various primary and secondary sources for the patents' exp
iration dates, sales volume and units sold, and characteristics of drugs in
the sample markets.
Study Design. The study was designed to determine significant factors using
the study model. developed under the assumption that the off-patented mark
et is an imperfectly segmented market.
Principal Findings. After patent expiration, the originators' prices contin
ued to increase, while the price of multiple-source drugs decreased signifi
cantly over time. By the fourth year after patent expiration, originators'
sales had decreased 12 percent in dollars and 30 percent in quantity. Multi
ple-source drugs increased their sales twofold in dollars and threefold in
quantity, and possessed about one-fourth (in dollars) and half (in quantity
) of the total market three years after entry.
Conclusion. After patent expiration, multiple-source drugs compete largely
with other multiple-source drugs in the price-sensitive sector, but indirec
tly with the originator in the price-insensitive sector. Originators have f
irst-mover advantages, and therefore have a market that is less price sensi
tive after multiple-source drugs enter. On the other hand, multiple-source
drugs target the price-sensitive sector, using their lower-priced drugs. Th
is trend may indicate that the off-patented market is imperfectly segmented
between the price-sensitive and insensitive sector. Consumers as a whole c
an gain from the entry of multiple-source drugs because the average price o
f the market continually declines after patent expiration.